<DOC>
	<DOCNO>NCT00123461</DOCNO>
	<brief_summary>The purpose study demonstrate safety effectiveness HectorolÂ® ( doxercalciferol ) capsule treat patient Stage 3 Stage 4 chronic kidney disease ( CKD ) secondary hyperparathyroidism vitamin D level normal range . Previous study doxercalciferol conduct patient low level vitamin D .</brief_summary>
	<brief_title>Study Safety Efficacy Doxercalciferol Patients With Chronic Kidney Disease , Stage 3 4 , Secondary Hyperparathyroidism</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Plasma iPTH value 110 pg/mL CKD Stage 3 subject 150 pg/mL CKD Stage 4 Serum 25hydroxyvitamin D level great equal 30 ng/mL CKD Stage 3 evidence glomerular filtration rate ( GFR ) abbreviate MDRD equation 3059 mL/min CKD Stage 4 evidence glomerular filtration rate ( GFR ) abbreviate MDRD equation 1529 mL/min Serum cCa &gt; 9.5 mg/dL Serum P &gt; 4.6 mg/dL Abnormal liver function Anticipated requirement maintenance hemodialysis Use active vitamin D sterol therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>